Rice Partnership, LLC recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
1099 ALAKEA STREET HONOLULU, HI 96813
As of the latest 13F report, the guru’s equity portfolio contained 113 stocks valued at a total of $317.00Mil. The top holdings were
According to GuruFocus data, these were Rice Partnership, LLC’s top five trades of the quarter.
iShares MSCI United Kingdom ETF
Rice Partnership, LLC reduced their investment in ARCA:EWU by 178,176 shares. The trade had a 1.5% impact on the equity portfolio. During the quarter, the stock traded for an average price of $28.98.
On 01/27/2023, iShares MSCI United Kingdom ETF traded for a price of $32.74 per share and a market cap of $3.39Bil. The stock has returned 1.05% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, iShares MSCI United Kingdom ETF has a price-earnings ratio of 11.64 and a price-book ratio of 1.61.
Procter & Gamble Co
Rice Partnership, LLC reduced their investment in NYSE:PG by 33,713 shares. The trade had a 1.37% impact on the equity portfolio. During the quarter, the stock traded for an average price of $140.19.
On 01/27/2023, Procter & Gamble Co traded for a price of $141.15 per share and a market cap of $332.99Bil. The stock has returned -8.53% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Procter & Gamble Co has a price-earnings ratio of 24.76, a price-book ratio of 7.67, a price-earnings-to-growth (PEG) ratio of 2.72, a EV-to-Ebitda ratio of 17.46 and a price-sales ratio of 4.41.
The price-to-GF Value ratio is 0.92, earning the stock a GF Value rank of 6.
International Business Machines Corp
During the quarter, Rice Partnership, LLC bought 22,810 shares of NYSE:IBM for a total holding of 53,739. The trade had a 1.01% impact on the equity portfolio. During the quarter, the stock traded for an average price of $137.94.
On 01/27/2023, International Business Machines Corp traded for a price of $134.45 per share and a market cap of $121.56Bil. The stock has returned 5.06% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 7 out of 10.
In terms of valuation, International Business Machines Corp has a price-earnings ratio of 76.39, a price-book ratio of 6.05, a EV-to-Ebitda ratio of 23.91 and a price-sales ratio of 2.00.
The price-to-GF Value ratio is 1.02, earning the stock a GF Value rank of 5.
VanEck Vietnam ETF
The guru sold out of their 191,818-share investment in BATS:VNM. Previously, the stock had a 0.82% weight in the equity portfolio. Shares traded for an average price of $11.89 during the quarter.
On 01/27/2023, VanEck Vietnam ETF traded for a price of $12.93 per share and a market cap of $543.71Mil. The stock has returned -32.64% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, VanEck Vietnam ETF has a price-earnings ratio of 10.92 and a price-book ratio of 1.78.
Abbott Laboratories
Rice Partnership, LLC reduced their investment in NYSE:ABT by 20,280 shares. The trade had a 0.63% impact on the equity portfolio. During the quarter, the stock traded for an average price of $103.54.
On 01/27/2023, Abbott Laboratories traded for a price of $111.07 per share and a market cap of $193.66Bil. The stock has returned -6.08% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Abbott Laboratories has a price-earnings ratio of 28.41, a price-book ratio of 5.43, a price-earnings-to-growth (PEG) ratio of 1.30, a EV-to-Ebitda ratio of 17.05 and a price-sales ratio of 4.39.
The price-to-GF Value ratio is 0.86, earning the stock a GF Value rank of 7.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
